Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: A possible role for SirT3 activation

Mitochondrion

Volumn 13, Issue 6, 2013, Pages 637-646

  Teodoro, João Soeiro ^a,b   Duarte, Filipe Valente ^a,b   Gomes, Ana Patrícia ^a,b   Varela, Ana Teresa ^a,b   Peixoto, Francisco Manuel ^c   Rolo, Anabela Pinto ^a,d   Palmeira, Carlos Marques ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Berberine; Liver bioenergetics; Mitochondrial function; Obesity; SirT3

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; BERBERINE; CALCIUM; CYTOCHROME C OXIDASE; OXYGEN; REACTIVE OXYGEN METABOLITE; RNA; SIRTUIN 3; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM METABOLISM; CELL ISOLATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; LIPID DIET; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RNA ISOLATION; WESTERN BLOTTING;

ACC; ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASE; AMPK; BBR; BERBERINE; BERBERINE-SUPPLEMENTED HFD GROUP; CARBONYLCYANIDE-P-TRIFLUOROMETHOXYPHENYLHYDRAZON; CONTROL LOW FAT DIET-FED GROUP; CTL; FAME; FATTY ACID METHYL ESTER; FCCP; FFA; FREE FATTY ACIDS; HFD; HIGH FAT DIET-FED GROUP; LIVER BIOENERGETICS; MITOCHONDRIAL FUNCTION; NAFLD; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE PHOSPHORYLATION; OXPHOS; RCR; REACTIVE OXYGEN SPECIES; RESPIRATORY CONTROL RATIO; ROS; SIRT3; SIRTUIN 3; T2D; TETRAPHENYLPHOSPHONIUM; TPP+; TYPE II DIABETES;

ADENOSINE TRIPHOSPHATE; ANIMALS; BASE SEQUENCE; BERBERINE; DIET, HIGH-FAT; DNA PRIMERS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER; OXIDATIVE PHOSPHORYLATION; RATS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; SIRTUIN 3;

EID: 84884937949     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2013.09.002     Document Type: Article

References (61)

1. Ahn B.-H., Kim H.-S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.-X., Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14447-14452.
2. Brautigan D.L., Ferguson-Miller S., Margoliash E. Mitochondrial cytochrome c: preparation and activity of native and chemically modified cytochromes c. Meth. Enzymol. 1978, 53:128-164.
3. Brusq J., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47:1281.
4. Bullen J.W., Bluher S., Kelesidis T., Mantzoros C.S. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1079-E1086.
5. Cantó C., Houtkooper R.H., Pirinen E., Youn D.Y., Oosterveer M.H., Cen Y., Fernandez-Marcos P.J., Yamamoto H., Andreux P.A., Cettour-Rose P., Gademann K., Rinsch C., Schoonjans K., Sauve A.A., Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012, 15:838-847.
6. Carley A.N., Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta 2005, 1734:112-126.
7. Chance B., Williams G.R. The respiratory chain and oxidative phosphorylation. Adv. Enzymol. Relat. Subj. Biochem. 1956, 17:65-134.
8. Cheng Z., Pang T., Gu M., Gao A.-H., Xie C.-M., Li J.-Y., Nan F.-J., Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta 2006, 1760:1682-1689.
9. Choudhury M., Jonscher K.R., Friedman J.E. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat. Aging 2011, 3:175-178.
10. Cimen H., Han M.-J., Yang Y., Tong Q., Koc H., Koc E.C. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 2010, 49:304-311.
11. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease. JAMA 2003, 289:3000-3004.
12. Domitrović R., Jakovac H., Blagojević G. Hepatoprotective activity of berberine is mediated by inhibition of TNF-α, COX-2, and iNOS expression in CCl(4)-intoxicated mice. Toxicology 2011, 280:33-43.
13. Du J., Zhou Y., Su X., Yu J.J., Khan S., Jiang H., Kim J. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011, 334(6057):806-809.
14. Estabrook R.W. Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. Meth. Enzymol. 1967, 10:41-47.
15. Fernandez-Marcos P.J., Jeninga E.H., Canto C. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Scientific reports 2012.
16. Gazotti P., Malmstron K., Crompton M. Preparation and assay of animal mitochondria and submitochondrial particles. Membrane Biochemistry: A Laboratory Manual on Transport and Bioenergetics 1979, 62-76. Springer-Verlag New York Inc. E. Carafoli, G. Semenza (Eds.).
17. Gomes A.P., Duarte F.V., Nunes P., Hubbard B.P., Teodoro J.S., Varela A.T., Jones J.G., Sinclair D.A., Palmeira C.M., Rolo A.P. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim. Biophys. Acta 2012, 1822(185):195.
18. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 1949, 177:751-766.
19. Haque M., Sanyal A.J. The metabolic abnormalities associated with nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 2002, 16:709-731.
20. Haslam D.W., James W.P.T. Obesity. Lancet 2005, 366:1197-1209.
21. Hirschey M., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D., Grueter C., Harris C., Biddinger S., Ilkayeva O. SIRT3 regulates fatty acid oxidation via reversible enzyme deacetylation. Nature 2010, 464:121.
22. Hirschey M.D., Shimazu T., Jing E., Grueter C.A., Collins A.M., Aouizerat B., Stančáková A., Goetzman E., Lam M.M., Schwer B., Stevens R.D., Muehlbauer M.J., Kakar S., Bass N.M., Kuusisto J., Laakso M., Alt F.W., Newgard C.B., Farese R.V., Kahn C.R., Verdin E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 2011, 44:177-190.
23. Huang J.-Y., Hirschey M.D., Shimazu T., Ho L., Verdin E. Mitochondrial sirtuins. Biochim. Biophys. Acta 2010, 1804:1645-1651.
24. Kamo N., Muratsugu M., Hongoh R., Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 1979, 49:105-121.
25. Kelley D.E., He J., Menshikova E.V., Ritov V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
26. Kendrick A.A., Choudhury M., Rahman S.M., McCurdy C.E., Friederich M., Van Hove J.L.K., Watson P.A., Birdsey N., Bao J., Gius D., Sack M.N., Jing E., Kahn C.R., Friedman J.E., Jonscher K.R. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem. J. 2011, 433:505-514.
27. Kim S.H., Shin E.-J., Kim E.-D., Bayaraa T., Frost S.C., Hyun C.-K. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. Biol. Pharm. Bull. 2007, 30:2120-2125.
28. Kong W.-J., Zhang H., Song D.-Q., Xue R., Zhao W., Wei J., Wang Y.-M., Shan N., Zhou Z.-X., Yang P., You X.-F., Li Z.-R., Si S.-Y., Zhao L.-X., Pan H.-N., Jiang J.-D. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metab. Clin. Exp. 2009, 58:109-119.
29. Kong X., Wang R., Xue Y., Liu X., Zhang H., Chen Y., Fang F., Chang Y. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010, 5:e11707.
30. Kuda O., Jelenik T., Jilkova Z., Flachs P., Rossmeisl M., Hensler M., Kazdová L., Ogston N., Baranowski M., Gorski J., Janovská P., Kus V., Polak J., Mohamed-Ali V., Burcelin R., Cinti S., Bryhn M., Kopecky J. n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a highfat diet. Diabetologia 2009, 52:941-951.
31. Lee Y., Kim W., Kim K., Yoon M., Cho H., Shen Y., Ye J., Lee C., Oh W., Kim C. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin resistant states. Diabetes 2006, 55:2256.
32. Leng S.H., Lu F.E., Xu L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 2004, 25:496-502.
33. Levine R., Haft D.E. Carbohydrate homeostasis. N. Engl. J. Med. 1970, 283:237-246.
34. Liu X., Li G., Zhu H., Huang L., Liu Y., Ma C., Qin C. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr. J. 2010, 57:881-893.
35. Lu S.-S., Yu Y.-L., Zhu H.-J., Liu X.-D., Liu L., Liu Y.-W., Wang P., Xie L., Wang G.-J. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J. Endocrinol. 2009, 200:159-165.
36. Palmeira C.M., Wallace K.B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol. 1997, 143:338-347.
37. Palmeira C.M., Moreno A.J., Madeira V. Interactions of herbicides 2, 4-D and dinoseb with liver mitochondrial bioenergetics. Toxicol. Appl. Pharmacol. 1994, 127:50-57.
38. Peixoto F., Vicente J., Madeira V. A comparative study of plant and animal mitochondria exposed to paraquat reveals that hydrogen peroxide is not related to the observed toxicity. Toxicol. In Vitro 2004, 18:733-739.
39. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S20-S27.
40. Pessayre D., Berson A., Fromenty B. Mitochondria in steatohepatitis. Semin. Liver Dis. 2001, 21:57-69.
41. Rolo A.P., Oliveira P.J., Moreno A.J., Palmeira C.M. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol. Sci. 2000, 57:177-185.
42. Shah P., Vella A., Basu A., Basu R., Adkins A., Schwenk W.F., Johnson C.M., Nair K.S., Jensen M.D., Rizza R.A. Elevated free fatty acids impair glucose metabolism in women: decreased stimulation of muscle glucose uptake and suppression of splanchnic glucose production during combined hyperinsulinemia and hyperglycemia. Diabetes 2003, 52:38-42.
43. Singer T.P. Determination of the activity of succinate, NADH, choline, and alpha-glycerophosphate dehydrogenases. Methods Biochem. Anal. 1974, 22:123-175.
44. Tauriainen E., Luostarinen M., Martonen E., Finckenberg P., Kovalainen M., Huotari A., Herzig K.-H., Lecklin A., Mervaala E. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J. Nutr. Metab. 2011, 2011:525094.
45. Teodoro J., Rolo A.P., Oliveira P.J., Palmeira C.M. Decreased ANT content in Zucker fatty rats: relevance for altered hepatic mitochondrial bioenergetics in steatosis. FEBS Lett. 2006, 580:2153-2157.
46. Teodoro J.S., Rolo A.P., Duarte F.V., Simões A.M., Palmeira C.M. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008, 8:367-376.
47. The Global Burden | International Diabetes Federation [WWW Document].idf.org (URL http://www.idf.org/diabetesatlas/5e/regional-overviews (last accessed 5.20.2013)).
48. Valdecantos M.P., Pérez-Matute P., González-Muniesa P., Prieto-Hontoria P.L., Moreno-Aliaga M.J., Martínez J.A. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity (Silver Spring) 2012, 20:1974-1983.
49. Wang C., Li J., Lv X., Zhang M., Song Y., Chen L., Liu Y. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur. J. Pharmacol. 2009, 620:131-137.
50. Wang Y., Huang Y., Lam K.S., Li Y., Wong W.T., Ye H., Lau C.W., Vanhoutte P.M., Xu A. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc. Res. 2009, 82:484-492.
51. Wang Y., Campbell T., Perry B. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet-and streptozotocin-induced diabetic rats. Metabolism 2011, 60:298-305.
52. Xia X., Yan J., Shen Y., Tang K., Yin J., Zhang Y., Yang D., Liang H., Ye J., Weng J. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One 2011, 6:e16556.
53. Yin J., Zhang H., Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr. Metab. Immune Disord. Drug Targets 2008, 8:99-111.
54. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008, 93:2559-2565.
55. Zhang H., Wei J., Xue R., Wu J.-D., Zhao W., Wang Z.-Z., Wang S.-K., Zhou Z.-X., Song D.-Q., Wang Y.-M., Pan H.-N., Kong W.-J., Jiang J.-D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2009, 59:285-292.
56. Zhou J.Y., Zhou S.-W. Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. Fitoterapia 2011, 82:184-189.
57. Zhou S., Palmeira C., Wallace K. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 2001, 121:151-157.
58. Zhou L., Yang Y., Wang X., Liu S., Shang W., Yuan G., Li F., Tang J., Chen M., Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007, 56:405-412.
59. Zhou L., Wang X., Shao L., Yang Y., Shang W., Yuan G., Jiang B., Li F., Tang J., Jing H., Chen M. Berberine acutely inhibits insulin secretion from beta-cells through 3',5-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology 2008, 149:4510-4518.
60. Zhou J., Zhou S., Tang J., Zhang K., Guang L., Huang Y., Xu Y., Ying Y., Zhang L., Li D. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur. J. Pharmacol. 2009, 606:262-268.
61. Zhou L., Wang X., Yang Y., Wu L., Li F., Zhang R., Yuan G., Wang N., Chen M., Ning G. Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes. BBA - Molecular Basis of Disease 2010, 1-9.